RT Journal Article
T1 In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
A1 Serrano-Conde, Esther
A1 Leyva, Alba
A1 Fuentes, Ana
A1 de Salazar, Adolfo
A1 Chueca, Natalia
A1 Perez-Castro, Sonia
A1 Regueiro, Benito
A1 Rojas, Almudena
A1 Mendoza, Joaquin
A1 Rojas, Jose
A1 Garcia, Federico
K1 B.1
K1 B.1.1.7
K1 B.1.351
K1 BNT162b2 mRNA
K1 SARS-CoV-2
K1 neutralization
K1 variants
AB SARS-CoV-2 variation represents a serious challenge to current COVID-19 vaccines. Recent reports suggest that B.1.351 and other variants may escape the neutralization activity of the antibodies generated by current vaccines. Ninety-nine healthcare workers undertaking BNT162b2 mRNA vaccination were sampled at baseline, on the day of the second dose, and 14 days after the latter. Neutralization activity against SARS-CoV-2 B.1, B.1.1.7 and B.1.351 was investigated using a Vero-E6 model. Eleven of the study participants had prior infection with SARS-CoV-2. Neutralization titers against the B.1 and the B.1.1.7 variants were not statistically different and were significantly higher than titers against the B.1.351 variant across pre-exposed and non-pre-exposed vaccinated individuals (p 1/80 after a single dose, while only 11% of non-exposed vaccinated individuals had titers >1/80. BNT162b2 mRNA-induced antibodies show a lower in vitro neutralizing activity against B.1.351 variant compared to neutralization against B.1.1.7 or B.1 variants. Interestingly, for individuals pre-exposed to SARS-CoV-2, one dose of BNT162b2 mRNA may be adequate to produce neutralizing antibodies against B.1.1.7 and B.1, while two doses of BNT162b2 mRNA provide optimal neutralizing antibody response against B.1.351 too.
PB Hindawi Limited
YR 2021
FD 2021-12-08
LK http://hdl.handle.net/10668/20020
UL http://hdl.handle.net/10668/20020
LA en
NO Serrano-Conde E, Leyva A, Fuentes A, de Salazar A, Chueca N, Pérez-Castro S, et al. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. Transbound Emerg Dis. 2022 Sep;69(5):2649-2655.
DS RISalud
RD Apr 7, 2025